- About Us
- News & Media
Safe Harbor Statement Under the Private Securities Litigation Reform Act, as amended:
With the exception of the historical statements, statements contained in this website may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identifiable by the use of the words "believes," "views," "expects," "projects," "hopes," "could," "will," "intends," "should," "estimate," "would," "may," "anticipates," "plans", "target", "goal" or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are subject to a number of risks and uncertainties that may, individually or collectively, cause actual results to differ materially from those contained in the forward-looking information, and are based on the current expectations, estimates, forecasts and projections of Innovus Pharmaceuticals, Inc. ("Innovus Pharma"). Many of the risks and uncertainties are outside the control of Innovus Pharma. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in Innovus Pharma's most recent annual report on Form 10-K and its other filings with the SEC. Copies of these filings are available from the SEC's website or the "Investors" section of this website. Forward-looking statements contained in this website speak only as of the date thereof. Except as required by law, Innovus Pharma undertakes no obligation to publicly release the results of any revisions or updates to these forward-looking statements that may be made to reflect events or circumstances after the date thereof, or to reflect the occurrence of unanticipated events. Innovus Pharma disclaims any intention to update this website to reflect actual subsequent events.
Zestra, Zestra Glide, Vesele, Sensum and Adroferti are either cosmetic and/or food supplements. The statements listed on the packaging of the products have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. EjectDelay is an FDA OTC monograph compliant drug indicated for treatment of premature ejaculation